
Pulmonologist

No OPD information available
Acute Respiratory Distress Syndrome (ARDS)
COVID-19
Cardiac Arrest
Cerebral Hypoxia
Severe Acute Respiratory Syndrome (SARS)
Cardiogenic Shock
Cramp-Fasciculation Syndrome
Craniectomy
Delirium
H1N1 Influenza
Heart Attack
Heart Failure
Heart Transplant
Long Haul COVID
Lung Transplant
Metabolic Acidosis
Pneumonia
Sepsis
Stroke
Carol L. Hodgson is a female medical professional who helps patients with different health problems like Acute Respiratory Distress Syndrome (ARDS), COVID-19, and heart issues. She also works with conditions like pneumonia, stroke, and sepsis. Carol uses her skills to treat patients who are very sick, such as those with severe lung problems or heart failure.
Carol talks to her patients in a kind and caring way, which helps them feel safe and understood. Patients trust her because she listens to their concerns and explains things clearly. She stays updated on the latest medical information by reading research studies and attending conferences to learn new treatments and techniques.
Carol works well with other medical professionals, like doctors and nurses, to give the best care to her patients. She shares her knowledge and collaborates with her colleagues to find the right solutions for each patient's needs. Her work has had a positive impact on many patients' lives, helping them recover from serious illnesses and improve their health.
One of Carol's notable publications is about developing a new way to measure patients' progress in clinical trials. She also conducted a clinical trial to study how early activity and mobilization can benefit patients on ventilators in intensive care. This trial was successfully completed and provided important information for improving patient care.
Overall, Carol L. Hodgson is a dedicated and skilled medical professional who works hard to help her patients and contribute to medical research. Her caring approach, commitment to learning, and collaboration with colleagues make her a valuable member of the healthcare team.
Enrollment Status: Completed
Published: December 18, 2023
Intervention Type: Behavioral
Study Drug:
Study Phase: Phase 3
